Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787776 | 1.00 | MAPT (0.46) | MAPTNPC1LMNAMEN1KMT2A | |
| SCHEMBL1786886 | 0.90 | ALDH1A1 (0.43) | MAPTNPC1LMNAMEN1KMT2A | |
| SCHEMBL1786888 | 0.90 | ALDH1A1 (0.43) | MAPTNPC1LMNAMEN1KMT2A | |
| SCHEMBL1786942 | 0.90 | MAPT (0.45) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL30794868 | 0.90 | MAPT (0.45) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL1791226 | 0.90 | MAPT (0.45) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL1791227 | 0.90 | MAPT (0.45) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL1786940 | 0.90 | MAPT (0.45) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL13721686 | 0.90 | P2RX7 (0.42) | MAPTNPC1LMNAMEN1KMT2A | |
| SCHEMBL1788841 | 0.90 | MCHR1 (0.42) | MAPTNPC1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629143-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2014-01-14 | — | — | US | claimed |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | claimed |
| US-8629143-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNQ3 | MAPT 3480/4885NPC1 326/4885LMNA 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.